TY - JOUR AU - Bray, F. AU - Ferlay, J. AU - Soerjomataram, I. AU - Siegel, R. L. AU - Torre, L. A. AU - Jemal, A. PY - 2018 DA - 2018// TI - Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries JO - CA Cancer J Clin VL - 68 UR - https://doi.org/10.3322/caac.21492 DO - 10.3322/caac.21492 ID - Bray2018 ER - TY - JOUR AU - Waks, A. G. AU - Winer, E. P. PY - 2019 DA - 2019// TI - Breast cancer treatment: a review JO - JAMA. VL - 321 UR - https://doi.org/10.1001/jama.2018.19323 DO - 10.1001/jama.2018.19323 ID - Waks2019 ER - TY - JOUR AU - Zurrida, S. AU - Veronesi, U. PY - 2015 DA - 2015// TI - Milestones in breast cancer treatment JO - Breast J VL - 21 UR - https://doi.org/10.1111/tbj.12361 DO - 10.1111/tbj.12361 ID - Zurrida2015 ER - TY - JOUR AU - Presti, D. AU - Quaquarini, E. PY - 2019 DA - 2019// TI - The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2- Metastatic Breast Cancer: Biological Mechanisms and New Treatments JO - Cancers (Basel) VL - 11 UR - https://doi.org/10.3390/cancers11091242 DO - 10.3390/cancers11091242 ID - Presti2019 ER - TY - JOUR AU - Beck, J. T. AU - Hortobagyi, G. N. AU - Campone, M. AU - Lebrun, F. AU - Deleu, I. PY - 2014 DA - 2014// TI - Rug HSo, et al. Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2 JO - Breast Cancer Res Treat VL - 43 UR - https://doi.org/10.1007/s10549-013-2814-5 DO - 10.1007/s10549-013-2814-5 ID - Beck2014 ER - TY - JOUR AU - Fabrice, A. AU - Eva, C. AU - Gabor, R. AU - Mario, C. AU - Sibylle, L. PY - 2019 DA - 2019// TI - S RH, et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer JO - N Engl J Med VL - 380 UR - https://doi.org/10.1056/NEJMoa1813904 DO - 10.1056/NEJMoa1813904 ID - Fabrice2019 ER - TY - JOUR AU - Jones, R. H. AU - Casbard, A. AU - Carucci, M. AU - Cox, C. AU - Butler, R. AU - Alchami, F. PY - 2020 DA - 2020// TI - Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial JO - Lancet Oncol VL - 21 UR - https://doi.org/10.1016/S1470-2045(19)30817-4 DO - 10.1016/S1470-2045(19)30817-4 ID - Jones2020 ER - TY - JOUR AU - Turner, N. C. AU - Slamon, D. J. AU - Ro, J. AU - Bondarenko, I. AU - Im, S. A. AU - Masuda, N. PY - 2018 DA - 2018// TI - Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1810527 DO - 10.1056/NEJMoa1810527 ID - Turner2018 ER - TY - JOUR AU - Im, S. A. AU - Lu, Y. S. AU - Bardia, A. AU - Harbeck, N. AU - Colleoni, M. AU - Franke, F. PY - 2019 DA - 2019// TI - Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer JO - N Engl J Med VL - 381 UR - https://doi.org/10.1056/NEJMoa1903765 DO - 10.1056/NEJMoa1903765 ID - Im2019 ER - TY - JOUR AU - Tower, H. AU - Ruppert, M. AU - Britt, K. PY - 2019 DA - 2019// TI - The Immune Microenvironment of Breast Cancer Progression JO - Cancers (Basel) VL - 11 UR - https://doi.org/10.3390/cancers11091375 DO - 10.3390/cancers11091375 ID - Tower2019 ER - TY - STD TI - Abrahamsson A, Rodriguez GV, Dabrosin C. Fulvestrant-mediated attenuation of the innate immune response decreases ER+ breast cancer growth in vivo more effectively than tamoxifen. Cancer Res. 2020:canres.1705.2020. ID - ref11 ER - TY - JOUR AU - Joffroy, C. M. AU - Buck, M. B. AU - Stope, M. B. AU - Popp, S. L. AU - Pfizenmaier, K. AU - Knabbe, C. PY - 2010 DA - 2010// TI - Antiestrogens Induce Transforming Growth Factor β–Mediated Immunosuppression in Breast Cancer JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-3292 DO - 10.1158/0008-5472.CAN-09-3292 ID - Joffroy2010 ER - TY - JOUR AU - Wang, X. AU - Simpson, E. R. AU - Brown, K. A. PY - 2015 DA - 2015// TI - Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer JO - J Steroid Biochem Mol Biol VL - 153 UR - https://doi.org/10.1016/j.jsbmb.2015.07.008 DO - 10.1016/j.jsbmb.2015.07.008 ID - Wang2015 ER - TY - JOUR AU - Purohit, A. AU - Newman, S. P. AU - Reed, M. J. PY - 2002 DA - 2002// TI - The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer JO - Breast Cancer Res VL - 4 UR - https://doi.org/10.1186/bcr425 DO - 10.1186/bcr425 ID - Purohit2002 ER - TY - JOUR AU - Magnani, L. AU - Frige, G. AU - Gadaleta, R. M. AU - Corleone, G. AU - Fabris, S. AU - Kempe, H. PY - 2017 DA - 2017// TI - Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer JO - Nat Genet VL - 49 UR - https://doi.org/10.1038/ng.3773 DO - 10.1038/ng.3773 ID - Magnani2017 ER - TY - JOUR AU - Kovats, S. PY - 2015 DA - 2015// TI - Estrogen receptors regulate innate immune cells and signaling pathways JO - Cell Immunol VL - 294 UR - https://doi.org/10.1016/j.cellimm.2015.01.018 DO - 10.1016/j.cellimm.2015.01.018 ID - Kovats2015 ER - TY - JOUR AU - Choi, J. AU - Gyamfi, J. AU - Jang, H. AU - Koo, J. S. PY - 2018 DA - 2018// TI - The role of tumor-associated macrophage in breast cancer biology JO - Histol Histopathol VL - 33 ID - Choi2018 ER - TY - JOUR AU - Segovia-Mendoza, M. AU - Morales-Montor, J. PY - 2019 DA - 2019// TI - Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer Physiopathology JO - Front Immunol VL - 10 UR - https://doi.org/10.3389/fimmu.2019.00348 DO - 10.3389/fimmu.2019.00348 ID - Segovia-Mendoza2019 ER - TY - JOUR AU - Vegeto, E. AU - Ghisletti, S. AU - Meda, C. AU - Etteri, S. AU - Belcredito, S. AU - Maggi, A. PY - 2004 DA - 2004// TI - Regulation of the lipopolysaccharide signal transduction pathway by 17beta-estradiol in macrophage cells JO - J Steroid Biochem Mol Biol VL - 91 UR - https://doi.org/10.1016/j.jsbmb.2004.02.004 DO - 10.1016/j.jsbmb.2004.02.004 ID - Vegeto2004 ER - TY - JOUR AU - Kramer, P. R. PY - 2004 DA - 2004// TI - S F Kramer, Guan G. 17 beta-estradiol regulates cytokine release through modulation of CD16 expression in monocytes and monocyte-derived macrophages JO - Arthritis Rheum VL - 50 UR - https://doi.org/10.1002/art.20309 DO - 10.1002/art.20309 ID - Kramer2004 ER - TY - JOUR AU - Rogers, A. AU - Eastell, R. PY - 2001 DA - 2001// TI - The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood JO - Bone. VL - 29 UR - https://doi.org/10.1016/S8756-3282(01)00468-9 DO - 10.1016/S8756-3282(01)00468-9 ID - Rogers2001 ER - TY - JOUR AU - Nilsson, N. AU - Carlsten, H. PY - 1994 DA - 1994// TI - Estrogen induces suppression of natural killer cell cytotoxicity and augmentation of polyclonal B cell activation JO - Cell Immunol VL - 158 UR - https://doi.org/10.1006/cimm.1994.1262 DO - 10.1006/cimm.1994.1262 ID - Nilsson1994 ER - TY - JOUR AU - Jiang, X. AU - Ellison, S. AU - Alarid, E. AU - Shapiro, D. J. PY - 2007 DA - 2007// TI - Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells JO - Oncogene. VL - 26 UR - https://doi.org/10.1038/sj.onc.1210197 DO - 10.1038/sj.onc.1210197 ID - Jiang2007 ER - TY - JOUR AU - Laffont, S. AU - Seillet, C. AU - Guéry, J. C. PY - 2017 DA - 2017// TI - Estrogen receptor-dependent regulation of dendritic cell development and function JO - Front Immunol VL - 8 UR - https://doi.org/10.3389/fimmu.2017.00108 DO - 10.3389/fimmu.2017.00108 ID - Laffont2017 ER - TY - JOUR AU - Liu, H. Y. AU - Buenafe, A. C. AU - Matejuk, A. AU - Ito, A. AU - Zamora, A. AU - Dwyer, J. PY - 2002 DA - 2002// TI - Estrogen inhibition of EAE involves effects on dendritic cell function JO - J Neurosci Res VL - 70 UR - https://doi.org/10.1002/jnr.10409 DO - 10.1002/jnr.10409 ID - Liu2002 ER - TY - JOUR AU - Xiao, B. G. AU - Liu, X. AU - Link, H. PY - 2004 DA - 2004// TI - Antigen-specific T cell functions are suppressed over the estrogen-dendritic cell-indoleamine 2, 3-dioxygenase axis JO - Steroids. VL - 69 UR - https://doi.org/10.1016/j.steroids.2004.05.019 DO - 10.1016/j.steroids.2004.05.019 ID - Xiao2004 ER - TY - JOUR AU - McMurray, R. W. AU - Ndebele, K. AU - Hardy, K. J. AU - Jenkins, J. K. PY - 2001 DA - 2001// TI - 17-β-estradiol suppresses IL-2 and IL-2 receptor JO - Cytokine. VL - 14 UR - https://doi.org/10.1006/cyto.2001.0900 DO - 10.1006/cyto.2001.0900 ID - McMurray2001 ER - TY - JOUR AU - Polanczyk, M. J. AU - Carson, B. D. AU - Subramanian, S. AU - Afentoulis, M. AU - Vandenbark, A. A. AU - Ziegler, S. F. PY - 2004 DA - 2004// TI - Cutting edge: estrogen drives expansion of the CD4+ CD25+ regulatory T cell compartment JO - J Immunol VL - 173 UR - https://doi.org/10.4049/jimmunol.173.4.2227 DO - 10.4049/jimmunol.173.4.2227 ID - Polanczyk2004 ER - TY - JOUR AU - Svoronos, N. AU - Perales-Puchalt, A. AU - Allegrezza, M. J. AU - Rutkowski, M. R. AU - Payne, K. K. AU - Tesone, A. J. PY - 2017 DA - 2017// TI - Tumor cell–independent estrogen signaling drives disease progression through mobilization of myeloid-derived suppressor cells JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-0502 DO - 10.1158/2159-8290.CD-16-0502 ID - Svoronos2017 ER - TY - JOUR AU - Polanczyk, M. J. AU - Hopke, C. AU - Vandenbark, A. A. AU - Offner, H. PY - 2007 DA - 2007// TI - Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1) JO - Int Immunol VL - 19 UR - https://doi.org/10.1093/intimm/dxl151 DO - 10.1093/intimm/dxl151 ID - Polanczyk2007 ER - TY - JOUR AU - Chung, H. H. AU - Or, Y. Z. AU - Shrestha, S. AU - Loh, J. T. AU - Lim, C. L. AU - Ong, Z. PY - 2017 DA - 2017// TI - Estrogen reprograms the activity of neutrophils to foster protumoral microenvironment during mammary involution JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/srep46485 DO - 10.1038/srep46485 ID - Chung2017 ER - TY - JOUR AU - Zhang, W. AU - Shen, Y. AU - Huang, H. AU - Pan, S. AU - Jiang, J. AU - Chen, W. PY - 2020 DA - 2020// TI - A Rosetta Stone for Breast Cancer: Prognostic Value and Dynamic Regulation of Neutrophil in Tumor Microenvironment JO - Front Immunol VL - 11 UR - https://doi.org/10.3389/fimmu.2020.01779 DO - 10.3389/fimmu.2020.01779 ID - Zhang2020 ER - TY - JOUR AU - Traboulsi, T. AU - Ezzy, M. E. AU - Gleason, J. L. AU - Mader, S. PY - 2017 DA - 2017// TI - Antiestrogens: structure-activity relationships and use in breast cancer treatment JO - J Mol Endocrinol VL - 58 UR - https://doi.org/10.1530/JME-16-0024 DO - 10.1530/JME-16-0024 ID - Traboulsi2017 ER - TY - JOUR AU - Behjati, S. AU - Frank, M. PY - 2009 DA - 2009// TI - The effects of tamoxifen on immunity JO - Curr Med Chem VL - 16 UR - https://doi.org/10.2174/092986709788803042 DO - 10.2174/092986709788803042 ID - Behjati2009 ER - TY - JOUR AU - Komi, J. AU - Lassila, O. PY - 1998 DA - 1998// TI - Antioestrogens enhance tumour necrosis factor receptor 2 (TNF-R2) expression and TNF-R2-mediated proliferation in activated T cells JO - Scand J Immunol VL - 48 UR - https://doi.org/10.1046/j.1365-3083.1998.00388.x DO - 10.1046/j.1365-3083.1998.00388.x ID - Komi1998 ER - TY - JOUR AU - Richards, J. O. AU - Albers, A. J. AU - Smith, T. S. AU - Tjoe, J. A. PY - 2016 DA - 2016// TI - NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells JO - Cancer Immunol Immunother VL - 65 UR - https://doi.org/10.1007/s00262-016-1885-7 DO - 10.1007/s00262-016-1885-7 ID - Richards2016 ER - TY - JOUR AU - Nalbandian, G. AU - Paharkova-Vatchkova, V. AU - Mao, A. AU - Nale, S. AU - Kovats, S. PY - 2005 DA - 2005// TI - The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation JO - J Immunol VL - 175 UR - https://doi.org/10.4049/jimmunol.175.4.2666 DO - 10.4049/jimmunol.175.4.2666 ID - Nalbandian2005 ER - TY - JOUR AU - Corriden, R. AU - Hollands, A. AU - Olson, J. AU - Derieux, J. AU - Lopez, J. AU - Chang, J. T. PY - 2015 DA - 2015// TI - Tamoxifen augments the innate immune function of neutrophils through modulation of intracellular ceramide JO - Nat Commun VL - 6 UR - https://doi.org/10.1038/ncomms9369 DO - 10.1038/ncomms9369 ID - Corriden2015 ER - TY - JOUR AU - Flores, R. AU - Döhrmann, S. AU - Schaal, C. AU - Hakkim, A. AU - Nizet, V. AU - Corriden, R. PY - 2016 DA - 2016// TI - The selective estrogen receptor modulator raloxifene inhibits neutrophil extracellular trap formation JO - Front Immunol VL - 7 UR - https://doi.org/10.3389/fimmu.2016.00566 DO - 10.3389/fimmu.2016.00566 ID - Flores2016 ER - TY - JOUR AU - Márquez-Garbán, D. C. AU - Deng, G. AU - Comin-Anduix, B. AU - Garcia, A. J. AU - Xing, Y. AU - Chen, H. -. W. PY - 2019 DA - 2019// TI - Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy JO - J Steroid Biochem Mol Biol VL - 193 UR - https://doi.org/10.1016/j.jsbmb.2019.105415 DO - 10.1016/j.jsbmb.2019.105415 ID - Márquez-Garbán2019 ER - TY - JOUR AU - Chan, M. S. AU - Wang, L. AU - Felizola, S. J. AU - Ueno, T. AU - Toi, M. AU - Loo, W. PY - 2012 DA - 2012// TI - Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients–an immunohistochemical study of Cd8+ and FOXp3+ using double immunostaining with correlation to the pathobiological response of the patients JO - Int J Biol Markers VL - 27 UR - https://doi.org/10.5301/JBM.2012.10439 DO - 10.5301/JBM.2012.10439 ID - Chan2012 ER - TY - JOUR AU - Jingxuan, W. AU - Qingyuan, Z. AU - Shi, J. AU - Meiyan, F. AU - Xinmei, K. AU - Shu, Z. PY - 2009 DA - 2009// TI - Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis JO - Exp Gerontol VL - 44 UR - https://doi.org/10.1016/j.exger.2009.03.003 DO - 10.1016/j.exger.2009.03.003 ID - Jingxuan2009 ER - TY - JOUR AU - Aggelakopoulou, M. AU - Kourepini, E. AU - Paschalidis, I. AU - Panoutsakopoulou, V. PY - 2016 DA - 2016// TI - ERβ in CD4+ T Cells Is Crucial for Ligand-Mediated Suppression of Central Nervous System Autoimmunity JO - J Immunol VL - 196 UR - https://doi.org/10.4049/jimmunol.1600246 DO - 10.4049/jimmunol.1600246 ID - Aggelakopoulou2016 ER - TY - JOUR AU - Rao, Q. AU - Chen, Y. AU - Yeh, C. -. R. AU - Ding, J. AU - Li, L. AU - Chang, C. PY - 2016 DA - 2016// TI - Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2 EMT/MMP9 signals JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.5467 DO - 10.18632/oncotarget.5467 ID - Rao2016 ER - TY - JOUR AU - Sung, N. AU - García, M. D. S. AU - Dambaeva, S. AU - Beaman, K. D. AU - Gilman-Sachs, A. AU - Kwak-Kim, J. PY - 2016 DA - 2016// TI - Gonadotropin-releasing hormone analogues lead to pro-inflammatory changes in T lymphocytes JO - Am J Reprod Immunol VL - 76 UR - https://doi.org/10.1111/aji.12522 DO - 10.1111/aji.12522 ID - Sung2016 ER - TY - JOUR AU - Xie, S. AU - Chen, M. AU - Yan, B. AU - He, X. AU - Chen, X. AU - Li, D. PY - 2014 DA - 2014// TI - Identification of a role for the PI3K/AKT/mTOR signaling pathway in innate immune cells JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0094496 DO - 10.1371/journal.pone.0094496 ID - Xie2014 ER - TY - JOUR AU - Abu-Eid, R. AU - Samara, R. N. AU - Ozbun, L. AU - Abdalla, M. Y. AU - Berzofsky, J. A. AU - Friedman, K. M. PY - 2014 DA - 2014// TI - Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway JO - Cancer Immunol Res VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-14-0095 DO - 10.1158/2326-6066.CIR-14-0095 ID - Abu-Eid2014 ER - TY - JOUR AU - Blanco, B. AU - Herrero-Sánchez, C. AU - Rodríguez-Serrano, C. AU - Sánchez-Barba, M. AU - Cañizo, M. C. PY - 2015 DA - 2015// TI - Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function JO - Int Immunopharmacol VL - 28 UR - https://doi.org/10.1016/j.intimp.2015.07.032 DO - 10.1016/j.intimp.2015.07.032 ID - Blanco2015 ER - TY - JOUR AU - Sai, J. AU - Owens, P. AU - Novitskiy, S. V. AU - Hawkins, O. E. AU - Vilgelm, A. E. AU - Yang, J. PY - 2017 DA - 2017// TI - PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and anti-PD1 responses JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-2142 DO - 10.1158/1078-0432.CCR-16-2142 ID - Sai2017 ER - TY - JOUR AU - Choi, J. -. H. AU - Kim, K. H. AU - Roh, K. -. H. AU - Jung, H. AU - Lee, A. AU - Lee, J. -. Y. PY - 2018 DA - 2018// TI - A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice JO - Oncoimmunology. VL - 7 UR - https://doi.org/10.1080/2162402X.2017.1421890 DO - 10.1080/2162402X.2017.1421890 ID - Choi2018 ER - TY - JOUR AU - Aragoneses-Fenoll, L. AU - Ojeda, G. AU - Montes-Casado, M. AU - Acosta-Ampudia, Y. AU - Dianzani, U. AU - Portolés, P. PY - 2018 DA - 2018// TI - T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response JO - Front Immunol VL - 9 UR - https://doi.org/10.3389/fimmu.2018.00332 DO - 10.3389/fimmu.2018.00332 ID - Aragoneses-Fenoll2018 ER - TY - JOUR AU - Teo, Z. L. AU - Versaci, S. AU - Dushyanthen, S. AU - Caramia, F. AU - Savas, P. AU - Mintoff, C. P. PY - 2017 DA - 2017// TI - Combined CDK4/6 and PI3Kα inhibition is synergistic and immunogenic in triple-negative breast cancer JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/0008-5472.CAN-17-2210 DO - 10.1158/0008-5472.CAN-17-2210 ID - Teo2017 ER - TY - JOUR AU - Leverrier, Y. AU - Okkenhaug, K. AU - Sawyer, C. AU - Bilancio, A. AU - Vanhaesebroeck, B. AU - Ridley, A. J. PY - 2003 DA - 2003// TI - Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages JO - J Biol Chem VL - 278 UR - https://doi.org/10.1074/jbc.M306649200 DO - 10.1074/jbc.M306649200 ID - Leverrier2003 ER - TY - JOUR AU - Houslay, D. M. AU - Anderson, K. E. AU - Chessa, T. AU - Kulkarni, S. AU - Fritsch, R. AU - Downward, J. PY - 2016 DA - 2016// TI - Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells JO - Sci Signal VL - 9 UR - https://doi.org/10.1126/scisignal.aae0453 DO - 10.1126/scisignal.aae0453 ID - Houslay2016 ER - TY - JOUR AU - Schmid, M. C. AU - Avraamides, C. J. AU - Dippold, H. C. AU - Franco, I. AU - Foubert, P. AU - Ellies, L. G. PY - 2011 DA - 2011// TI - Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kg, A Single Convergent Point Promoting Tumor Inflammation and Progression JO - Cancer Cell VL - 19 UR - https://doi.org/10.1016/j.ccr.2011.04.016 DO - 10.1016/j.ccr.2011.04.016 ID - Schmid2011 ER - TY - JOUR AU - Kaneda, M. M. AU - Messer, K. S. AU - Ralainirina, N. AU - Li, H. AU - Leem, C. J. AU - Gorjestani, S. PY - 2016 DA - 2016// TI - PI3Kγ is a molecular switch that controls immune suppression JO - Nature. VL - 539 UR - https://doi.org/10.1038/nature19834 DO - 10.1038/nature19834 ID - Kaneda2016 ER - TY - JOUR AU - Henau, O. AU - Rausch, M. AU - Winkler, D. AU - Campesato, L. F. AU - Liu, C. AU - Cymerman, D. H. PY - 2016 DA - 2016// TI - Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells JO - Nature. VL - 539 UR - https://doi.org/10.1038/nature20554 DO - 10.1038/nature20554 ID - Henau2016 ER - TY - JOUR AU - Goulielmaki, E. AU - Bermudez-Brito, M. AU - Andreou, M. AU - Tzenaki, N. AU - Tzardi, M. AU - Ed, B. PY - 2018 DA - 2018// TI - Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages JO - Cell Death Dis VL - 9 UR - https://doi.org/10.1038/s41419-018-0717-4 DO - 10.1038/s41419-018-0717-4 ID - Goulielmaki2018 ER - TY - JOUR AU - Ali, K. AU - Soond, D. R. AU - Pineiro, R. AU - Hagemann, T. AU - Pearce, W. AU - Lim, E. L. PY - 2014 DA - 2014// TI - Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer JO - Nature. VL - 510 UR - https://doi.org/10.1038/nature13444 DO - 10.1038/nature13444 ID - Ali2014 ER - TY - JOUR AU - Soond, D. R. AU - Bjørgo, E. AU - Moltu, K. AU - Dale, V. Q. AU - Patton, D. T. AU - Torgersen, K. M. PY - 2010 DA - 2010// TI - PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans JO - Blood. VL - 115 UR - https://doi.org/10.1182/blood-2009-07-232330 DO - 10.1182/blood-2009-07-232330 ID - Soond2010 ER - TY - JOUR AU - Chiu, H. AU - Mallya, S. AU - Nguyen, P. AU - Mai, A. AU - Jackson, L. V. AU - Winkler, D. G. PY - 2017 DA - 2017// TI - The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation JO - Front Immunol VL - 8 UR - https://doi.org/10.3389/fimmu.2017.00747 DO - 10.3389/fimmu.2017.00747 ID - Chiu2017 ER - TY - JOUR AU - Gato-Cañas, M. PY - 2015 DA - 2015// TI - Morentin XMd, Blanco-Luquin I, Fernandez-Irigoyen J, Zudaire I, Liechtenstein T, et al. A core of kinase-regulated interactomes defines the neoplastic MDSC lineage JO - Oncotarget. VL - 6 UR - https://doi.org/10.18632/oncotarget.4746 DO - 10.18632/oncotarget.4746 ID - Gato-Cañas2015 ER - TY - JOUR AU - Arranz, A. AU - Doxaki, C. AU - Vergadi, E. AU - Torre, Y. M. AU - Vaporidi, K. AU - Lagoudaki, E. D. PY - 2012 DA - 2012// TI - Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization JO - Proc Natl Acad Sci U S A VL - 109 UR - https://doi.org/10.1073/pnas.1119038109 DO - 10.1073/pnas.1119038109 ID - Arranz2012 ER - TY - JOUR AU - Nandagopal, N. AU - Ali, A. K. AU - Komal, A. K. AU - Lee, S. -. H. PY - 2014 DA - 2014// TI - The Critical Role of IL-15-PI3K-mTOR Pathway in Natural Killer Cell Effector Functions JO - Front Immunol VL - 5 UR - https://doi.org/10.3389/fimmu.2014.00187 DO - 10.3389/fimmu.2014.00187 ID - Nandagopal2014 ER - TY - JOUR AU - Marçais, A. AU - Cherfils-Vicini, J. AU - Viant, C. AU - Degouve, S. AU - Viel, S. AU - Fenis, A. PY - 2014 DA - 2014// TI - The metabolic checkpoint kinase mTOR is essential for interleukin-15 signaling during NK cell development and activation JO - Nat Immunol VL - 15 UR - https://doi.org/10.1038/ni.2936 DO - 10.1038/ni.2936 ID - Marçais2014 ER - TY - JOUR AU - Haidinger, M. AU - Poglitsch, M. AU - Geyeregger, R. AU - Kasturi, S. AU - Zeyda, M. AU - Zlabinger, G. J. PY - 2010 DA - 2010// TI - A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation JO - J Immunol VL - 185 UR - https://doi.org/10.4049/jimmunol.1000296 DO - 10.4049/jimmunol.1000296 ID - Haidinger2010 ER - TY - JOUR AU - Zheng, Y. AU - Delgoffe, G. M. AU - Meyer, C. F. AU - Chan, W. AU - Powell, J. D. PY - 2009 DA - 2009// TI - Anergic T cells are metabolically anergic JO - J Immunol VL - 183 UR - https://doi.org/10.4049/jimmunol.0803510 DO - 10.4049/jimmunol.0803510 ID - Zheng2009 ER - TY - JOUR AU - Pollizzi, K. N. AU - Patel, C. H. AU - Sun, I. -. H. AU - Oh, M. -. H. AU - Waickman, A. T. AU - Wen, J. PY - 2015 DA - 2015// TI - mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation JO - J Clin Invest VL - 125 UR - https://doi.org/10.1172/JCI77746 DO - 10.1172/JCI77746 ID - Pollizzi2015 ER - TY - JOUR AU - Chaoul, N. AU - Fayolle, C. AU - Desrues, B. AU - Oberkampf, M. AU - Tang, A. AU - Ladant, D. PY - 2015 DA - 2015// TI - Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-15-0454 DO - 10.1158/0008-5472.CAN-15-0454 ID - Chaoul2015 ER - TY - JOUR AU - Daniel, C. AU - Wennhold, K. AU - Kim, H. -. J. AU - Boehmer, H. PY - 2010 DA - 2010// TI - Enhancement of antigen-specific Treg vaccination in vivo JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.1007422107 DO - 10.1073/pnas.1007422107 ID - Daniel2010 ER - TY - JOUR AU - Cao, G. AU - Wang, Q. AU - Li, G. AU - Meng, Z. AU - Liu, H. AU - Tong, J. PY - 2016 DA - 2016// TI - mTOR inhibition potentiates cytotoxicity of Vγ4 γδ T cells via up-regulating NKG2D and TNF-α JO - J Leukoc Biol VL - 100 UR - https://doi.org/10.1189/jlb.5A0116-053RR DO - 10.1189/jlb.5A0116-053RR ID - Cao2016 ER - TY - JOUR AU - Li, H. AU - Pauza, C. D. PY - 2011 DA - 2011// TI - Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro JO - Cancer Immunol Immunother VL - 60 UR - https://doi.org/10.1007/s00262-010-0945-7 DO - 10.1007/s00262-010-0945-7 ID - Li2011 ER - TY - JOUR AU - Procaccini, C. AU - Rosa, V. D. AU - Galgani, M. AU - Abanni, L. AU - Calì, G. AU - Porcellini, A. PY - 2010 DA - 2010// TI - An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness JO - Immunity. VL - 33 UR - https://doi.org/10.1016/j.immuni.2010.11.024 DO - 10.1016/j.immuni.2010.11.024 ID - Procaccini2010 ER - TY - JOUR AU - Rosa, V. D. AU - Galgani, M. AU - Porcellini, A. AU - Colamatteo, A. AU - Santopaolo, M. AU - Zuchegna, C. PY - 2015 DA - 2015// TI - Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants JO - Nat Immunol VL - 16 UR - https://doi.org/10.1038/ni.3269 DO - 10.1038/ni.3269 ID - Rosa2015 ER - TY - JOUR AU - Deng, J. AU - Wang, E. S. AU - Jenkins, R. W. AU - Li, S. AU - Dries, R. AU - Yates, K. PY - 2018 DA - 2018// TI - CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-17-0915 DO - 10.1158/2159-8290.CD-17-0915 ID - Deng2018 ER - TY - JOUR AU - Schaer, D. A. AU - Beckmann, R. P. AU - Dempsey, J. A. AU - Huber, L. AU - Forest, A. AU - Amaladas, N. PY - 2018 DA - 2018// TI - The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade JO - Cell Rep VL - 22 UR - https://doi.org/10.1016/j.celrep.2018.02.053 DO - 10.1016/j.celrep.2018.02.053 ID - Schaer2018 ER - TY - JOUR AU - Goel, S. AU - DeCristo, M. J. AU - Watt, A. C. AU - BrinJones, H. AU - Sceneay, J. AU - Li, B. B. PY - 2017 DA - 2017// TI - CDK4/6 inhibition triggers anti-tumour immunity JO - Nature. VL - 548 UR - https://doi.org/10.1038/nature23465 DO - 10.1038/nature23465 ID - Goel2017 ER - TY - JOUR AU - Dabydeen, S. A. AU - Kang, K. AU - Díaz-Cruz, E. S. AU - Alamri, A. AU - Axelrod, M. L. AU - Bouker, K. B. PY - 2015 DA - 2015// TI - Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance JO - Carcinogenesis. VL - 36 UR - https://doi.org/10.1093/carcin/bgu237 DO - 10.1093/carcin/bgu237 ID - Dabydeen2015 ER - TY - JOUR AU - Dehghani, B. AU - Foster, S. AU - Kurniawan, A. AU - Lopez, F. J. AU - Sherman, L. S. PY - 2009 DA - 2009// TI - Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis JO - Glia VL - 57 UR - https://doi.org/10.1002/glia.20805 DO - 10.1002/glia.20805 ID - Dehghani2009 ER - TY - JOUR AU - Li, B. AU - Li, Y. AU - Wang, X. Y. AU - Yan, Z. Q. AU - Liu, H. AU - Liu, G. R. PY - 2015 DA - 2015// TI - Profile of differentially expressed intratumoral cytokines to predict the immune-polarizing side effects of tamoxifen in breast cancer treatment JO - Am J Cancer Res VL - 5 ID - Li2015 ER - TY - STD TI - Huhn D, Martí-Rodrigo P, Mouron S, Hansel C, Tschapalda K, Haggblad M, et al. Estrogen deprivation triggers an immunosuppressive phenotype in breast cancer cells. bioRxiv. 2019:715136. ID - ref81 ER - TY - JOUR AU - Rugo, H. S. AU - Delord, J. -. P. AU - Im, S. -. A. AU - Ott, P. A. AU - Piha-Paul, S. A. AU - Bedard, P. L. PY - 2018 DA - 2018// TI - Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-3452 DO - 10.1158/1078-0432.CCR-17-3452 ID - Rugo2018 ER - TY - JOUR AU - Nanda, R. AU - Chow, L. Q. AU - Dees, E. C. AU - Berger, R. AU - Gupta, S. AU - Geva, R. PY - 2016 DA - 2016// TI - Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.64.8931 DO - 10.1200/JCO.2015.64.8931 ID - Nanda2016 ER - TY - JOUR AU - Jaini, R. AU - Loya, M. G. AU - Eng, C. PY - 2017 DA - 2017// TI - Immunotherapeutic target expression on breast tumors can be amplified by hormone receptor antagonism: a novel strategy for enhancing efficacy of targeted immunotherapy JO - Oncotarget. VL - 8 UR - https://doi.org/10.18632/oncotarget.15812 DO - 10.18632/oncotarget.15812 ID - Jaini2017 ER - TY - JOUR AU - Komi, J. AU - Lassila, O. PY - 2000 DA - 2000// TI - Toremifene increases the expression of intercellular adhesion molecule-1 (ICAM-1) on MCF-7 breast cancer cells and Jurkat cells JO - Scand J Immunol VL - 51 UR - https://doi.org/10.1046/j.1365-3083.2000.00653.x DO - 10.1046/j.1365-3083.2000.00653.x ID - Komi2000 ER - TY - JOUR AU - Mor, G. AU - Kohen, F. AU - Garcia-Velasco, J. AU - Nilsen, J. AU - Brown, W. AU - Song, J. PY - 2000 DA - 2000// TI - Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen JO - J Steroid Biochem Mol Biol VL - 73 UR - https://doi.org/10.1016/S0960-0760(00)00081-9 DO - 10.1016/S0960-0760(00)00081-9 ID - Mor2000 ER - TY - JOUR AU - Svensson, S. AU - Abrahamsson, A. AU - Rodriguez, G. V. AU - Olsson, A. -. K. AU - Jensen, L. AU - Cao, Y. PY - 2015 DA - 2015// TI - CCL2 and CCL5 are novel therapeutic targets for estrogen-dependent breast cancer JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-15-0204 DO - 10.1158/1078-0432.CCR-15-0204 ID - Svensson2015 ER - TY - JOUR AU - Cuzick, J. S. I. AU - Cawthorn, S. PY - 2015 DA - 2015// TI - Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71171-4 DO - 10.1016/S1470-2045(14)71171-4 ID - Cuzick2015 ER - TY - JOUR AU - Schild-Hay, L. J. AU - Leil, T. A. AU - Divi, R. L. AU - Olivero, O. A. AU - Weston, A. AU - Poirier, M. C. PY - 2009 DA - 2009// TI - Tamoxifen Induces Expression of Immune Response–Related Genes in Cultured Normal Human Mammary Epithelial Cells JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-2806 DO - 10.1158/0008-5472.CAN-08-2806 ID - Schild-Hay2009 ER - TY - JOUR AU - Albrengues, J. AU - Shields, M. A. AU - Ng, D. AU - Park, C. G. AU - Ambrico, A. AU - Poindexter, M. E. PY - 2018 DA - 2018// TI - Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice JO - Science VL - 361 UR - https://doi.org/10.1126/science.aao4227 DO - 10.1126/science.aao4227 ID - Albrengues2018 ER - TY - JOUR AU - Simpson, E. R. PY - 2003 DA - 2003// TI - Sources of estrogen and their importance JO - J Steroid Biochem Mol Biol VL - 86 UR - https://doi.org/10.1016/S0960-0760(03)00360-1 DO - 10.1016/S0960-0760(03)00360-1 ID - Simpson2003 ER - TY - JOUR AU - Placido, S. AU - Gallo, C. AU - Laurentiis, M. AU - Bisagni, G. AU - Arpino, G. AU - Sarobba, M. G. PY - 2018 DA - 2018// TI - Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30116-5 DO - 10.1016/S1470-2045(18)30116-5 ID - Placido2018 ER - TY - JOUR AU - Straub, R. H. PY - 2007 DA - 2007// TI - The complex role of estrogens in inflammation JO - Endocr Rev VL - 28 UR - https://doi.org/10.1210/er.2007-0001 DO - 10.1210/er.2007-0001 ID - Straub2007 ER - TY - JOUR AU - Braun, D. P. AU - Crist, K. A. AU - Shaheen, F. AU - Staren, E. D. AU - Andrews, S. AU - Parker, J. PY - 2005 DA - 2005// TI - Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity JO - Am J Surg VL - 190 UR - https://doi.org/10.1016/j.amjsurg.2005.06.013 DO - 10.1016/j.amjsurg.2005.06.013 ID - Braun2005 ER - TY - JOUR AU - Generali, D. AU - Bates, G. AU - Berruti, A. AU - Brizzi, M. P. AU - Campo, L. AU - Bonardi, S. PY - 2009 DA - 2009// TI - Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-1507 DO - 10.1158/1078-0432.CCR-08-1507 ID - Generali2009 ER - TY - JOUR AU - Guo, D. AU - Liu, X. AU - Zeng, C. AU - Cheng, L. AU - Song, G. AU - Hou, X. PY - 2019 DA - 2019// TI - Estrogen receptor β activation ameliorates DSS-induced chronic colitis by inhibiting inflammation and promoting Treg differentiation JO - Int Immunopharmacol VL - 77 UR - https://doi.org/10.1016/j.intimp.2019.105971 DO - 10.1016/j.intimp.2019.105971 ID - Guo2019 ER - TY - JOUR AU - Aponte-López, A. AU - Fuentes-Pananá, E. M. AU - Cortes-Muñoz, D. AU - Muñoz-Cruz, S. PY - 2018 DA - 2018// TI - Mast Cell, the Neglected Member of the Tumor Microenvironment: Role in Breast Cancer JO - J Immunol Res VL - 2018 UR - https://doi.org/10.1155/2018/2584243 DO - 10.1155/2018/2584243 ID - Aponte-López2018 ER - TY - JOUR AU - Bense, R. D. AU - Sotiriou, C. AU - Piccart-Gebhart, M. J. AU - Haanen, J. B. AU - Vugt, M. A. AU - Vries, E. G. PY - 2016 DA - 2016// TI - Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer JO - J Natl Cancer Inst VL - 109 UR - https://doi.org/10.1093/jnci/djw192 DO - 10.1093/jnci/djw192 ID - Bense2016 ER - TY - JOUR AU - Mello-Grand, M. AU - Singh, V. AU - Ghimenti, C. AU - Scatolini, M. AU - Regolo, L. AU - Grosso, E. PY - 2010 DA - 2010// TI - Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer JO - Breast Cancer Res Treat VL - 121 UR - https://doi.org/10.1007/s10549-010-0887-y DO - 10.1007/s10549-010-0887-y ID - Mello-Grand2010 ER - TY - JOUR AU - Dunbier, A. K. AU - Ghazoui, Z. AU - Anderson, H. AU - Salter, J. AU - Nerurkar, A. AU - Osin, P. PY - 2013 DA - 2013// TI - Molecular profiling of aromatase inhibitor–treated postmenopausal breast tumors identifies immune-related correlates of resistance JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-1000 DO - 10.1158/1078-0432.CCR-12-1000 ID - Dunbier2013 ER - TY - JOUR AU - Gao, Q. AU - Patani, N. AU - Dunbier, A. K. AU - Ghazoui, Z. AU - Zvelebil, M. AU - Martin, L. -. A. PY - 2014 DA - 2014// TI - Effect of aromatase inhibition on functional gene modules in estrogen receptor–positive breast cancer and their relationship with antiproliferative response JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2602 DO - 10.1158/1078-0432.CCR-13-2602 ID - Gao2014 ER - TY - JOUR AU - Liang, X. AU - Briaux, A. AU - Becette, V. AU - Benoist, C. AU - Boulai, A. AU - Chemlali, W. PY - 2018 DA - 2018// TI - Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609) JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0670-9 DO - 10.1186/s13045-018-0670-9 ID - Liang2018 ER - TY - JOUR AU - Skriver, S. K. AU - Jensen, M. -. B. AU - Knoop, A. S. AU - Ejlertsen, B. AU - Laenkholm, A. -. V. PY - 2020 DA - 2020// TI - Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial JO - Breast Cancer Res VL - 22 UR - https://doi.org/10.1186/s13058-020-01285-8 DO - 10.1186/s13058-020-01285-8 ID - Skriver2020 ER - TY - JOUR AU - Stemke-Hale, K. AU - Gonzalez-Angulo, A. M. AU - Lluch, A. AU - Neve, R. M. AU - Kuo, W. -. L. AU - Davies, M. PY - 2008 DA - 2008// TI - An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-07-6854 DO - 10.1158/0008-5472.CAN-07-6854 ID - Stemke-Hale2008 ER - TY - JOUR AU - Baselga, J. AU - Im, S. -. A. AU - Iwata, H. AU - Cortés, J. AU - Laurentiis, M. D. AU - Jiang, Z. PY - 2017 DA - 2017// TI - Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet Oncol VL - 20 UR - https://doi.org/10.1016/S1470-2045(17)30376-5 DO - 10.1016/S1470-2045(17)30376-5 ID - Baselga2017 ER - TY - JOUR AU - Krop, I. E. AU - Mayer, I. A. AU - Ganju, V. AU - Dickler, M. AU - Johnston, S. AU - Morales, S. PY - 2016 DA - 2016// TI - Pictilisib for oestrogen receptor-positive, aromatase inhibitorresistant, advanced or metastatic breast cancer (FERGI): A randomised, double-blind, placebo-controlled, phase 2 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)00106-6 DO - 10.1016/S1470-2045(16)00106-6 ID - Krop2016 ER - TY - JOUR AU - Juric, D. AU - Janku, F. AU - Rodón, J. AU - Burris, H. A. AU - Mayer, I. A. AU - Schuler, M. PY - 2019 DA - 2019// TI - Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial JO - JAMA Oncol VL - 5 UR - https://doi.org/10.1001/jamaoncol.2018.4475 DO - 10.1001/jamaoncol.2018.4475 ID - Juric2019 ER - TY - JOUR AU - Dickler, M. N. AU - Saura, C. AU - Richards, D. A. AU - Krop, I. E. AU - Cervantes, A. AU - Bedard, P. L. PY - 2018 DA - 2018// TI - Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-18-0613 DO - 10.1158/1078-0432.CCR-18-0613 ID - Dickler2018 ER - TY - JOUR AU - Kok, K. AU - Geering, B. AU - Vanhaesebroeck, B. PY - 2009 DA - 2009// TI - Regulation of phosphoinositide 3-kinase expression in health and disease JO - Trends Biochem Sci VL - 34 UR - https://doi.org/10.1016/j.tibs.2009.01.003 DO - 10.1016/j.tibs.2009.01.003 ID - Kok2009 ER - TY - JOUR AU - Blanco, B. AU - Herrero-Sánchez, M. C. AU - Rodríguez-Serrano, C. AU - Sánchez-Barba, M. AU - Cañizo, M. C. D. PY - 2015 DA - 2015// TI - Profound blockade of T cell activation requires concomitant inhibition of different class I PI3K isoforms JO - Immunol Res VL - 62 UR - https://doi.org/10.1007/s12026-015-8648-y DO - 10.1007/s12026-015-8648-y ID - Blanco2015 ER - TY - JOUR AU - Crane, C. AU - Panner, A. AU - Murray, J. AU - Wilson, S. AU - Xu, H. AU - Chen, L. PY - 2009 DA - 2009// TI - PI (3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer JO - Oncogene. VL - 28 UR - https://doi.org/10.1038/onc.2008.384 DO - 10.1038/onc.2008.384 ID - Crane2009 ER - TY - JOUR AU - Carvalho, S. AU - Milanezi, F. AU - Costa, J. L. AU - Amendoeira, I. AU - Schmitt, F. PY - 2010 DA - 2010// TI - PIKing the right isoform: the emergent role of the p110β subunit in breast cancer JO - Virchows Archiv An Int J Pathol VL - 456 UR - https://doi.org/10.1007/s00428-010-0881-0 DO - 10.1007/s00428-010-0881-0 ID - Carvalho2010 ER - TY - JOUR AU - Crowder, R. J. AU - Phommaly, C. AU - Tao, Y. AU - Hoog, J. AU - Luo, J. AU - Perou, C. M. PY - 2009 DA - 2009// TI - PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor positive breast cancer JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-4450 DO - 10.1158/0008-5472.CAN-08-4450 ID - Crowder2009 ER - TY - JOUR AU - Hosford, S. R. AU - Dillon, L. M. AU - Bouley, S. J. AU - Rosati, R. AU - Yang, W. AU - Chen, V. S. PY - 2017 DA - 2017// TI - Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-15-2764 DO - 10.1158/1078-0432.CCR-15-2764 ID - Hosford2017 ER - TY - JOUR AU - Araki, K. AU - Miyoshi, Y. PY - 2018 DA - 2018// TI - Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer JO - Breast Cancer VL - 25 UR - https://doi.org/10.1007/s12282-017-0812-x DO - 10.1007/s12282-017-0812-x ID - Araki2018 ER - TY - JOUR AU - Zhang, B. AU - Ma, Y. AU - Guo, H. AU - Sun, B. AU - Niu, R. AU - Ying, G. PY - 2009 DA - 2009// TI - Akt2 is required for macrophage chemotaxis JO - Eur J Immunol VL - 39 UR - https://doi.org/10.1002/eji.200838809 DO - 10.1002/eji.200838809 ID - Zhang2009 ER - TY - JOUR AU - Wang, J. AU - Wan, W. AU - Sun, R. AU - Liu, Y. AU - Sun, X. AU - Ma, D. PY - 2008 DA - 2008// TI - Reduction of Akt2 expression inhibits chemotaxis signal transduction in human breast cancer cells JO - Cell Signal VL - 20 UR - https://doi.org/10.1016/j.cellsig.2007.12.023 DO - 10.1016/j.cellsig.2007.12.023 ID - Wang2008 ER - TY - JOUR AU - O'Shaughnessy, J. AU - Beck, J. T. AU - Royce, M. PY - 2018 DA - 2018// TI - Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer JO - Cancer Treat Rev VL - 69 UR - https://doi.org/10.1016/j.ctrv.2018.07.013 DO - 10.1016/j.ctrv.2018.07.013 ID - O'Shaughnessy2018 ER - TY - JOUR AU - Zeng, H. PY - 2017 DA - 2017// TI - mTOR signaling in immune cells and its implications for cancer immunotherapy JO - Cancer Lett VL - 408 UR - https://doi.org/10.1016/j.canlet.2017.08.038 DO - 10.1016/j.canlet.2017.08.038 ID - Zeng2017 ER - TY - JOUR AU - Powell, J. D. AU - Lerner, C. G. AU - Schwartz, R. H. PY - 1999 DA - 1999// TI - Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation JO - J Immunol VL - 162 UR - https://doi.org/10.4049/jimmunol.162.5.2775 DO - 10.4049/jimmunol.162.5.2775 ID - Powell1999 ER - TY - JOUR AU - Mercalli, A. AU - Calavita, I. AU - Dugnani, E. AU - Citro, A. AU - Cantarelli, E. AU - Nano, R. PY - 2013 DA - 2013// TI - Rapamycin unbalances the polarization of human macrophages to M1 JO - Immunology. VL - 140 UR - https://doi.org/10.1111/imm.12126 DO - 10.1111/imm.12126 ID - Mercalli2013 ER - TY - JOUR AU - Chen, W. AU - Ma, T. AU - Shen, X. -. n. AU - Xia, X. -. f. AU - Xu, G. -. d. AU - Bai, X. -. l. PY - 2012 DA - 2012// TI - Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-2684 DO - 10.1158/0008-5472.CAN-11-2684 ID - Chen2012 ER - TY - JOUR AU - Deng, Y. AU - Yang, J. AU - Luo, F. AU - Qian, J. AU - Liu, R. AU - Zhang, D. PY - 2018 DA - 2018// TI - mTOR-mediated glycolysis contributes to the enhanced suppressive function of murine tumor-infiltrating monocytic myeloid-derived suppressor cells JO - Cancer Immunol Immunother VL - 67 UR - https://doi.org/10.1007/s00262-018-2177-1 DO - 10.1007/s00262-018-2177-1 ID - Deng2018 ER - TY - JOUR AU - Wu, T. AU - Zhao, Y. AU - Wang, H. AU - Shao, L. AU - Wang, R. AU - Lu, J. PY - 2016 DA - 2016// TI - mTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors JO - Sci Rep VL - 6 UR - https://doi.org/10.1038/srep20250 DO - 10.1038/srep20250 ID - Wu2016 ER - TY - JOUR AU - Amiel, E. AU - Everts, B. AU - Freitas, T. C. AU - King, I. L. AU - Curtis, J. D. AU - Pearce, E. L. PY - 2012 DA - 2012// TI - Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice JO - J Immunol VL - 189 UR - https://doi.org/10.4049/jimmunol.1103741 DO - 10.4049/jimmunol.1103741 ID - Amiel2012 ER - TY - JOUR AU - Ni, C. AU - Fang, Q. -. Q. AU - Chen, W. -. Z. AU - Jiang, J. -. X. AU - Jiang, Z. AU - Ye, J. PY - 2020 DA - 2020// TI - Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+γδ1 Treg cells JO - Signal Transduct Target Ther VL - 5 UR - https://doi.org/10.1038/s41392-020-0129-7 DO - 10.1038/s41392-020-0129-7 ID - Ni2020 ER - TY - JOUR AU - Cristofanilli, M. AU - Turner, N. C. AU - Bondarenko, I. AU - Ro, J. AU - Im, S. -. A. AU - Masuda, N. PY - 2016 DA - 2016// TI - Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial17 JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00613-0 DO - 10.1016/S1470-2045(15)00613-0 ID - Cristofanilli2016 ER - TY - JOUR AU - Tripathy, D. AU - Im, S. -. A. AU - Colleoni, M. AU - Franke, F. AU - Bardia, A. AU - Harbeck, N. PY - 2018 DA - 2018// TI - Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30292-4 DO - 10.1016/S1470-2045(18)30292-4 ID - Tripathy2018 ER - TY - JOUR AU - Sledge, G. W. AU - Toi, M. AU - Neven, P. AU - Sohn, J. AU - Inoue, K. AU - Pivot, X. PY - 2019 DA - 2019// TI - The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial JO - JAMA Oncol VL - 6 UR - https://doi.org/10.1001/jamaoncol.2019.4782 DO - 10.1001/jamaoncol.2019.4782 ID - Sledge2019 ER - TY - JOUR AU - Watanabe, S. AU - Kawamoto, S. AU - Ohtani, N. AU - Hara, E. PY - 2017 DA - 2017// TI - Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases JO - Cancer Sci VL - 108 UR - https://doi.org/10.1111/cas.13184 DO - 10.1111/cas.13184 ID - Watanabe2017 ER - TY - JOUR AU - Lau, L. AU - David, G. PY - 2019 DA - 2019// TI - Pro- and anti-tumorigenic functions of the senescence-associated secretory phenotype JO - Expert Opin Ther Targets VL - 23 UR - https://doi.org/10.1080/14728222.2019.1565658 DO - 10.1080/14728222.2019.1565658 ID - Lau2019 ER - TY - JOUR AU - Martinez, G. J. AU - Pereira, R. M. AU - Äijö, T. AU - Kim, E. Y. AU - Marangoni, F. AU - Pipkin, M. E. PY - 2015 DA - 2015// TI - The transcription factor NFAT promotes exhaustion of activated CD8+ T cells JO - Immunity. VL - 42 UR - https://doi.org/10.1016/j.immuni.2015.01.006 DO - 10.1016/j.immuni.2015.01.006 ID - Martinez2015 ER - TY - JOUR AU - Schmid, P. AU - Cortes, J. AU - Pusztai, L. AU - McArthur, H. AU - Kümmel, S. AU - Bergh, J. PY - 2020 DA - 2020// TI - Pembrolizumab for Early Triple-Negative Breast Cancer JO - N Engl J Med VL - 382 UR - https://doi.org/10.1056/NEJMoa1910549 DO - 10.1056/NEJMoa1910549 ID - Schmid2020 ER - TY - JOUR AU - Schmid, P. AU - Adams, S. AU - Rugo, H. S. AU - Schneeweiss, A. AU - Barrios, C. H. AU - Iwata, H. PY - 2019 DA - 2019// TI - IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo)+ nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC) JO - J Clin Oncol VL - 37 ID - Schmid2019 ER - TY - JOUR AU - Zhang, J. AU - Bu, X. AU - Wang, H. AU - Zhu, Y. AU - Geng, Y. AU - Nihira, N. T. PY - 2018 DA - 2018// TI - Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance JO - Nature. VL - 553 UR - https://doi.org/10.1038/nature25015 DO - 10.1038/nature25015 ID - Zhang2018 ER - TY - JOUR AU - Hu, Z. Y. AU - Xie, N. AU - Tian, C. AU - Yang, X. AU - Liu, L. AU - Li, J. PY - 2018 DA - 2018// TI - Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance JO - EBioMedicine. VL - 32 UR - https://doi.org/10.1016/j.ebiom.2018.05.015 DO - 10.1016/j.ebiom.2018.05.015 ID - Hu2018 ER - TY - JOUR AU - Waks, A. G. AU - Stover, D. G. AU - Guerriero, J. L. AU - Dillon, D. AU - Barry, W. T. AU - Gjini, E. PY - 2019 DA - 2019// TI - The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy JO - Clin Cancer Res VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-19-0173 DO - 10.1158/1078-0432.CCR-19-0173 ID - Waks2019 ER -